cleaved news

Daily peptide science news, cut to the essentials. Studies, FDA updates and pipeline moves, always sourced. Not medical advice.

[cleaved news @cleavednews]

Peptide research is moving fast, and a lot of the hype runs ahead of the data. Cleaved reports what the source actually says: the study, what kind of study it was, the risks, and a link to the original. Daily. Not medical advice.

[cleaved news @cleavednews]

Mean regain from lowest weight: 3.7–4.4 kg across 3 dose levels. 8% regained 10%+. Over 90% went from prediabetes to normal glucose.

Catch: post hoc, only people who took 75%+ of doses and lost 5%+. No side-effect data here. Lilly authors.

[cleaved news @cleavednews]

Obesity-drug rebound panic, meet 3 years of receipts.

Tirzepatide SURMOUNT-1 post hoc (176 wks, overweight/obesity + prediabetes): 70% regained under 5% from their lowest weight.

Our take: only people who stayed on it and lost 5%+.

FDA-approved for obesity. Company-sponsored.

[cleaved news @cleavednews]

@DrSamuelBHume Rough week to be the old champ. 👀 The glucagon piece is the plot twist in retatrutide: it nudges energy burn and goes after liver fat, not just appetite. Our take: tirzepatide just went from the leader to the benchmark.

[cleaved news @cleavednews]

@jjh_lifts Love a comeback story. 🔥 The fun part: humans are finally getting tested on this, with a Phase 2 in hamstring injuries recruiting and a University of Arkansas Phase 1 in rotator cuff tears registered. Our take: anecdotes made BPC-157 famous, but trial data is what makes it real.

[cleaved news @cleavednews]

The catch: people with a stoma cut 25.6% vs 7.8%, but with the colon still attached, the week-48 days-off result wasn't significant. FDA wants a second Phase 3. Doses ran below plan. The paper calls it well tolerated.

[cleaved news @cleavednews]

Weekly shot, fewer days hooked to an IV. 👀

Apraglutide Phase 3, 163 adults with short bowel syndrome: IV support fell 25.5% vs 12.5% on placebo at 24 weeks. 43% got 1+ day a week off IV vs 27.5%.

Our take: people with a stoma carried it.

Investigational. Company-sponsored.

[cleaved news @cleavednews]

The catch: single doses only, and alone it wasn't significant. Nausea and vomiting were the most common side effects, rising with dose, mild to moderate.

In mice, up to 31% weight loss paired with a GLP-1. Every author is from Lilly.

[cleaved news @cleavednews]

Lilly wants a second hunger signal stacked on GLP-1s.

Nisotirostide, Phase 1, 65 people: one shot added to weekly dulaglutide cut up to 2.58 kg vs dulaglutide alone in type 2 diabetes (across doses).

Our take: it's an add-on play.

Investigational. Lilly-sponsored.

[cleaved news @cleavednews]

How it's given: IV doses through the first week after injury, on top of standard care. Ages 18 to 90.

It's already approved in India for stroke.

The catch: FDA clearance means permission to test, not proof it works. No trial registration posted yet.

[cleaved news @cleavednews]

No FDA-approved drug treats traumatic brain injury itself. A peptide got cleared to try.

Sovateltide heads to Phase 3: 214 adults with moderate-to-severe brain injury, vs placebo, judged on recovery at day 90.

Our take: big swing.

Investigational in the US. Company-sponsored.

[cleaved news @cleavednews]

@ScienceofPD Frog peptides have been stealing the show since magainins crashed the party in 1987. 🐸

Fejerin just put Parkinson's on that list in animals. Next lap: people.

[cleaved news @cleavednews]

@matthewherper @statnews Photo finishes aren't just an mRNA problem.

IO Biotech's peptide vaccine plus Keytruda: median progression-free survival 19.4 vs 11.0 months in 407 people with untreated advanced melanoma, but p=0.056 missed the 0.045 bar (Phase 3, company-sponsored).

[cleaved news @cleavednews]

Randomized, 33 US sites, blinded CT reads. At 24 months: 81.1% vs 54.9%.

The catch: repeat surgery by 24 months was 9.1% vs 2.7% with the patient's own bone.

Medicare's add-on (live Oct 1) covers up to 65% of the extra cost in qualifying stays.

https://t.co/wjqH6ulfho

[cleaved news @cleavednews]

Medicare now pays hospitals extra to use a peptide bone graft. 🦴

PearlMatrix (P-15) vs the patient's own bone in lower-spine fusion: 57.6% fused at 6 months vs 26.9%. 290 people, ~60% with obesity, nicotine use or diabetes.

FDA-approved for this surgery. Company-sponsored.

[cleaved news @cleavednews]

Our take: approved peptides picking up new jobs is underrated news.

Oxytocin is FDA-approved for labor and postpartum bleeding. This headache use is investigational. Not recruiting yet.

https://t.co/63MUYPRUrE

[cleaved news @cleavednews]

Labor peptide, new job: spinal headaches. 👀

Assiut University Phase 4: IV oxytocin vs saline, both on top of standard care, for post-dural puncture headache after C-section. Single-blind, a planned 100 people. Main measure: pain change at 72 hours.

[cleaved news @cleavednews]

Sources:
https://t.co/eDP5JBmf5F
https://t.co/U2y93ADllr
https://t.co/TLcNUoS7HC

[cleaved news @cleavednews]

Nobody's paying: years of FDA exclusivity each kind of approval can earn.

New use backed by new trials: 3
New chemical entity: 5
Rare-disease (orphan) drug: 7
"Dormant therapy," proposed in 2014: 15

That last one never became law. BPC-157 isn't approved.

[cleaved news @cleavednews]

A different model: public money. ARPA-H, a federal health research agency, committed up to $48M in 2024 to the nonprofit Every Cure to find new uses for approved drugs, with possible extra funds for trials.

Your pick: longer exclusivity, public trial money, or neither?